Izhevsk company STMpharm has launched sales of Okobrinol anti-glaucoma drops (brinzolamide/timolol). The combination drug is intended for patients with elevated intraocular pressure (open-angle glaucoma or ocular hypertension) where control with a single active ingredient is insufficient.
The drug is sold through the Pharmaimpex pharmacy chain, which comprises over 800 pharmacies across 25 regions, including Udmurtia, Tatarstan, Bashkortostan, the Mari El Republic, Perm Krai, the Khanty-Mansi and Yamalo-Nenets Autonomous Okrugs, among others.
is manufactured at the facilities of the Turkish company World Medicine, which specializes in ophthalmic products. The production uses active pharmaceutical ingredients of Italian (brinzolamide) and Indian (timolol) origin.
According to data from the Russian State Register of Medicines (GRLS), five drugs with an identical combination of active ingredients are currently present on the Russian market, apart from Okobrinol: two Russian ones (Borgitol Solopharm from Groteks and Brinzolol Duo from Otisipharm) – as well as Brinarga from India’s Sentiss Pharma, Azarga from Novartis, and Brinzopt Plus from Romania’s Rompharm.
STMpharm is a regional pharmaceutical company specializing in the production and marketing of probiotics, notably the Maxiflor line, and dietary supplements. It also acts as a distributor or local partner, introducing foreign drugs to the Russian market.
